Analyst spells out unclear future for Aduhelm and competitors

13 January 2022
iv_biotech_hospital_big

Research from industry analyst GlobalData underscores the uncertainty surrounding the prospects for Aduhelm (aducanumab), the newly-approved Alzheimer’s med from Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523).

In a much-anticipated  decision, announced this week, the US Centers for Medicare & Medicaid Services (CMS) opted not to offer broad coverage of the therapy to Medicare recipients.

Patients will be able to gain access to the treatment only if they are enrolled in a clinical trial, an outcome which severely limits the number of eligible recipients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology